UroAlert - GU Oncology Weekly

July 31, 2025

Videos

Peer-to-Peer Clinical Conversations

The State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer - Leslie Ballas, Parminder Singh & Mark Tyson

Leslie Ballas

Sam Chang moderates a multidisciplinary panel with Parminder Singh, Mark Tyson, and Leslie Ballas on bladder preservation for muscle-invasive bladder cancer.

C3NIRA Trial Findings in High-Risk Prostate Cancer Population - Ana Aparicio

Ana Aparicio

Oliver Sartor speaks with Ana Aparicio about data on aggressive variant prostate cancer.

Beyond the Abstracts

Metastatic Renal Cell Carcinoma: Synchronous vs. Metachronous Metastatic Disease and Its Impact on Cancer Control in the IO-Combination Era-Real World Experiences from a Multi-Institutional Cohort - Beyond the Abstract

A Prognostic Model for Survival of Patients with Metastatic Upper Tract Urothelial Carcinoma with First-Line Systemic Therapy - Beyond the Abstract

Conference Coverage

ASCO 2025: Prognostic Value of PSMA PET Against CHAARTED Criteria in an ENZAMET Sub-Cohort

ASCO 2025: 177Lu-PSMA-617 Consolidation Therapy Post Docetaxel in Patients with De-Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial

ASCO 2025: Trials-in-Progress – PUNCH03: A Phase II Study of Disitamab Vedotin Combined with Tislelizumab and Bacillus Calmette-Guerin (BCG) in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO 2025: BULLSEYE Discussion: Radioligand Therapies Unplugged: Is It Time to Break up with Androgen Deprivation Therapy?

ASCO 2025: SOGUG-NEOWIN: A Phase 2, Open-Label, Multicenter, Multinational Interventional Trial Evaluating the Efficacy and Safety of Erdafitinib Monotherapy and the Combination of Erdafitinib and Cetrelimab as Neoadjuvant Treatment in Cisplatin

Physician-Scientist Review Articles

ERBB2 Alterations in Circulating Tumor DNA in Patients with Metastatic Urothelial Cancer - Expert Commentary

Combining Immune Checkpoint Inhibition with Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis.

Robot-Assisted Radical Cystectomy with Ureterocutaneostomy: A Potentially Optimal Solution for Octogenarian and Frail Patients with Bladder Cancer.

ERBB2 Alterations in Circulating Tumor DNA in Patients with Metastatic Urothelial Cancer - Expert Commentary

ERBB2/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer

Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100.

Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy.

Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.

Treatment Patterns for Non-Muscle Invasive Bladder Cancer during the Bacillus Calmette-Guerin shortage.

Bladder cancer prevalence and diagnostic test accuracy: French results from the IDENTIFY study.

Long-term effect of treatment for non-muscle invasive bladder cancer on Quality of life: a cross-sectional study.

A Genital-Sparing Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion: A Case Report Using the hinotori™ Surgical Robot System.

Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what's new in 2025?

Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for MIBC in the United States - Expert Commentary

Adverse In-hospital Outcomes According to Pelvic Lymph Node Dissection at Partial Cystectomy.

Liquid Biopsy: Current advancements in clinical practice for bladder cancer.

Penile & Urethral Cancers

Medical-Seeking Behavior, Psychological Experiences, and Treatment Expectations of Patients With Penile Cancer Before Operation: A Qualitative Study.

Temporal Trends and Differences in Inpatient Palliative Care Use in Metastatic Penile Cancer Patients.

Diagnosis, Treatment and Survival From Penile Cancer: Real-World Data From the National Health Service England Between 2013 and 2020.

Excision of Penile Squamous Cell Carcinoma Is Associated With High Rates of Positive Surgical Margins.

Lymphovascular Invasion Predicts Cancer-Specific Mortality in Penile Localized Squamous Cell Carcinoma - Beyond the Abstract

Renal Cancer

Interobserver Reproducibility of Pelvicalyceal Invasion in Renal Cell Carcinoma Nephrectomies Among Genitourinary Pathologists.

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Treatment-Induced Gene Expression Changes in Metastatic Renal Cell Carcinoma: Insights from a Syngeneic Mouse Model.

The Anesthesiologic Impact of Single-Port Robot-Assisted Partial Nephrectomy: A Tertiary Referral Comparative Analysis Between Full-Flank Transperitoneal, Retroperitoneal, and Supine Lower Anterior Access (LAA).

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma.

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.

Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors.

Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project.

Metastatic Renal Cell Carcinoma: Synchronous vs. Metachronous Metastatic Disease and Its Impact on Cancer Control in the IO-Combination Era-Real World Experiences from a Multi-Institutional Cohort - Beyond the Abstract

Evaluation of 3,606 Renal Cell Tumors for TFE3 Rearrangements and TFEB Alterations via Fluorescence in Situ Hybridization, Next Generation Sequencing, and GPNMB Immunohistochemistry - Beyond the Abstract

Prostate Cancer

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Blue Earth Therapeutics Initiates Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Lutetium (177Lu) rhPSMA-10.1 Injection in Metastatic Castrate Resistant Prostate Cance

[177Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan.

The Role of Genomic Scores in the Management of Prostate Cancer Patients: A Comprehensive Narrative Review.

Integrating 68Ga-PSMA-11 PET/CT with Clinical Risk Factors for Enhanced Prostate Cancer Progression Prediction.

Synergistic Efficacy of WST11-VTP and P-Selectin-Targeted Nanotherapy in a Preclinical Prostate Cancer Model.

Racial Disparities in the Use of MRI and PET Scan Among Medicare Beneficiaries With Prostate Cancer.

Rewriting Androgen-Targeted Therapy Resistance with Non-coding RNAs in Prostate Cancer Treatment.

Transperineal Free-Hand Prostate Fusion Biopsy with AI-Driven Auto-Contouring: First Results of a Prospective Study.

Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.

Histopathologic Yields and Concordance of In-Bore MRI-targeted Biopsy for Prostate Cancer Diagnosis.

Smarter Screening and Treatment (S3T): Mitigating Harm via Age- and Prostate-Specific Antigen-Stratified Screening.

Perioperative Complications and In-Hospital Mortality After Radical Prostatectomy in Prostate Cancer Patients with a History of Heart Valve Replacement.

Genes Encoding Multiple Modulators of the Immune Response Are Methylated in the Prostate Tumor Microenvironment of African Americans.

Clarity Successfully Completes $203 Million Institutional Placement

Co-PSMA Trial: Recruitment Successfully Completed

Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115).

The 31st Annual Prostate Cancer Foundation Scientific Retreat Report.

Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.

Comparing Multigene Molecular Testing Results of MRI-Target Versus Systematic Prostate Needle Biopsies of Candidates for and Under Active Surveillance.

Prostate MRI Using Deep Learning Reconstruction in Response to Cancer Screening Demands-A Systematic Review and Meta-Analysis.

Impact of hormone sensitivity status on aberrant expression of CK7, CK20, CDX2, GATA3 and TTF1 in prostate cancer.

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer.

Real-World Experience of 18F-PSMA-1007 Positron Emission Tomography-Computed Tomography Scanning for Initial Staging of High-Risk Nonmetastatic Prostate Cancer: Scan Results and Treatment Decisions.

High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement.

Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.

Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.

Oncological Outcomes After Robotic Salvage Radical Prostatectomy in Patients Primarily Treated With Focal Versus Radiation Therapy: A Junior ERUS/YAU Collaborative Study.

Clinical Outcomes of Patients With Metastatic Prostate Cancer With Microsatellite Instability Treated With Pembrolizumab.

Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy.

Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT-based nomogram.

Transcutaneous perineal-ultrasound guided prostate biopsy in men with rectal amputation.

National Cancer System Characteristics and Global Pan-Cancer Outcomes

Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol - Beyond the Abstract

177Lu-PSMA-617 Consolidation Therapy after Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial - Beyond the Abstract

A Comparison of Surgical Outcomes Between Outpatient and Inpatient Robot-Assisted Radical Prostatectomy: A Systematic Review and Meta-Analysis - Beyond the Abstract

Upper Tract Tumors

Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial Carcinoma.

Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma.

External Validation of Current Quality Care Metrics after Radical Nephroureterectomy - Beyond the Abstract

Testicular Cancer

Is Human Chorionic Gonadotropin a Reliable Marker for Testicular Germ Cell Tumor? New Perspectives for a More Accurate Diagnosis.

Impact and Risk Factors of Diagnostic Delay in Patients With Testicular Cancer: A Multicenter Retrospective Study.

Beyond germ cell tumors: focus on Leydig cell neoplasms from a single-center experience.

MicroRNA-371-373 Cluster Extracellular Vesicle-Based Communication in Testicular Germ Cell Tumors - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC